Medicare
CMS Unveils Preliminary List of 101 Generic Drugs for Medicare $2 Out-of-Pocket Plan
Medicare $2 Drug List Model, generic drugs, out-of-pocket costs, medication adherence, health outcomes, CMS Innovation Center
CMS Prepares for Second Round of Medicare Drug Price Negotiation Program
Medicare Drug Price Negotiation Program, CMS, drug price negotiations, Inflation Reduction Act, Part D drugs, maximum fair prices (MFPs)
Novo Nordisk’s Ozempic Expected to Face Medicare Price Negotiations in 2025
Ozempic, Medicare, price negotiations, Novo Nordisk, diabetes medication, Inflation Reduction Act
Appeals Court Revives PhRMA’s Challenge to IRA’s Medicare Drug Price Negotiation Program
PhRMA, Inflation Reduction Act, Medicare Drug Price Negotiation Program, Fifth Circuit Court of Appeals, drug pricing, healthcare litigation
Biden Administration Announces Historic Lower Drug Prices for Medicare Beneficiaries
Biden Administration, Medicare, Drug Prices, Inflation Reduction Act, Prescription Drug Costs
Landmark Medicare Negotiations Set Prices for 10 Key Drugs, Projecting Billions in Savings
Medicare, drug prices, Biden administration, pharmaceutical companies, Inflation Reduction Act, prescription drugs, seniors, healthcare costs
Novo Nordisk Faces Setback in IRA Litigation, Vows to Appeal
Novo Nordisk, IRA lawsuit, Medicare price negotiations, legal setback, appeal
IRA Drug Price Reductions Unlikely to Harm Biotech Innovation, Studies Suggest
Inflation Reduction Act, IRA, drug price negotiations, biotech innovation, Medicare, pharmaceutical industry
President Biden Highlights Achievements in Lowering Prescription Drug Costs as He Steps Down from Re-election Campaign
President Biden, drug pricing, re-election campaign, Medicare, Inflation Reduction Act, prescription drug costs, health care costs, pharmaceutical industry
AstraZeneca Appeals IRA Loss, Reiterates Constitutional Challenge to Drug Price Negotiations
AstraZeneca, IRA, Medicare, Drug Price Negotiation, Constitutional Challenge, Appeal